The 27 dropouts,
which included the five subjects mentioned previously,
were allocated across the three cohorts as follows:
9, placebo; 9, GC; and 9, UC-II. The final dropout rate
was 14 %. Subjects’ dropout reasons are summarized in
Fig. 1. No subject withdrew from the trial due to an adverse
event attributable to any study product.